Background
==========

Nitric oxide (NO) is a short-lived gaseous lipophilic molecule produced in almost all tissues and organs \[[@B1],[@B2]\]. It is a free radical that exerts a variety of biological actions under both physiological and pathological conditions \[[@B3]\]. NO is formed from its precursor L-arginine by a family of NO synthases (NOSs). NOS system consists of three distinct isoforms, encoded by three distinct genes, including neuronal (nNOS or NOS-1), inducible (iNOS or NOS-2), and endothelial (eNOS or NOS-3). The gene encoding eNOS is located on chromosome 7 (7q35-q36) and contains 26 exons, with an entire length of 21 kb \[[@B3],[@B4]\].

NO has numerous functions in the kidney, including control of renal and glomerular hemodynamics, by interfering at multiple pathological and physiologically critical steps of nephron function. NO dilates both the afferent and the efferent arteriole, augmenting the glomerular filtration rate (GFR) and influencing renal sodium handling \[[@B5]\]. NO also mediates pressure natriuresis, maintenance of medullary perfusion, decrease of tubuloglomerular reabsorption, and modulation of renal sympathetic nerve activity \[[@B6]\]. The net effect of NO in the kidney is to promote natriuresis and diuresis, along with renal adaptation to dietary salt intake \[[@B7],[@B8]\].

eNOS gene has been considered a potential candidate gene to diabetic nephropathy (DN) susceptibility. Since 1998, several polymorphisms of the eNOS gene have been identified, and their association with various diseases has been explored. Three polymorphisms have been the subject of research in relation to DN, however the results are highly variable. The polymorphisms potentially associated with DN are a 27-bp repeat in intron 4 (VNTR), the T-786C single nucleotide polymorphism (SNP) in the promoter region (rs2070744), and G894T missense mutation in exon 7 (rs1799983) \[[@B9]\]. Some of these polymorphisms are associated with reduction of either eNOS activity (-786C in the promoter area) or plasma concentrations of NO (four repeats in intron 4) \[[@B2]\].

However, the potential association of eNOS gene variants with the induction and progression of DN remains controversial. Some authors found a higher frequency of eNOS polymorphisms in patients with end-stage renal disease (ESRD) and DN \[[@B10]-[@B17]\], but not all studies reported this association \[[@B18]-[@B20]\].

The objective of the present study was to evaluate if eNOS gene polymorphisms are associated with DN through a systematic review of the literature and a meta-analysis.

Results and discussion
======================

Three-hundred and nine studies were identified, and 281 were excluded based on review of titles and abstracts (70 animal experimental studies, 17 pharmacological studies, 86 without adequate cases or controls, 58 without the genes or polymorphisms of interest, 3 review articles, 5 meta-analysis, 35 studies with multiple publications of the same data presented with different titles, 7 no accesses to original data even after contacting authors). Twenty-eight articles were eligible and had the full text evaluated. Six studies were excluded due to lack of information regarding genotypic distribution. A total of 22 studies fulfilled the eligible criteria and were included for the meta-analysis (Figure  [1](#F1){ref-type="fig"}).

![Search strategy.](1471-2350-15-9-1){#F1}

Clinical characteristics of individual studies are described in Table  [1](#T1){ref-type="table"}. Regarding quality assessment, the phenotype definitions as cases or controls were appropriated, but none of the studies included information if genotyping was performed by personnel blinded to clinical status. Of the 22 studies included, 15 provided 4054/3405 cases/controls for 4b/a; 5 provided 1436/1286 cases/controls for T-786C; and 12 provided 3316/2765 cases/controls for G894T. The allelic frequency of 4b, T-786, and G894 in cases/controls was 6647/5702, 1863/1795, and 4691/4017 respectively (Table  [2](#T2){ref-type="table"}).

###### 

Baseline studies characteristics

  **Author**                      **Year**                                  **Polymorphism**      **Type of DM**   **Ethnicity**   **Cases/controls (n)**   **Criteria**                             **Male/female (%)**   **Age**       **DM duration (years)**
  ------------------------------- ----------------------------------------- --------------------- ---------------- --------------- ------------------------ ---------------------------------------- --------------------- ------------- -------------------------
  Ahluwalia et al. \[[@B21]\]     2008                                      G894T, 4a/b, T-786C   2                East Asians     Case (195)               Overt proteinuria                        35/65                 60.0 ± 6.15   16.5 ± 6.3
  Control (255)                   Normoalbuminuria                          41/59                 60.5 ± 5.7       15.6 ± 5.2                                                                                                            
  Bessa et al. \[[@B22]\]         2011                                      G894T                 2                African         Case (40)                Albuminuria \> 30 mg/24 h                21/19                 58.8 ± 12.5   19.4 ± 4.2
  Control (40)                    Albuminuria \< 30 mg/24 h                 17/23                 55.4 ± 8.8       15.3 ± 3.7                                                                                                            
  Cai et al. \[[@B23]\]           1998                                      G894T                 2                Whites          Case (116)               Microalbuminuria                         NA                    NA            NA
  Control (284)                   Normoalbuminuria                          NA                    NA               NA                                                                                                                    
  Degen et al. \[[@B24]\]         2001                                      4a/b                  1and 2           Whites          Case (207)               AER \>30 mg/24 h                         NA                    NA            \>10 yrs
  Control (418)                   AER \<30 mg/24 h                          NA                    NA               \>10 yrs                                                                                                              
  Ezzidi et al. \[[@B10]\]        2008                                      G894T, 4a/b, T-786C   2                African         Case (515)               AER \>30 mg/24 h                         46/54                 59.6 ± 10.8   13.5 ± 6.3
  Control (402)                   AER \<30 mg/24 h                          42/58                 59.1 ± 11.2      11.5 ± 6.2                                                                                                            
  Fujita et al. \[[@B25]\]        2000                                      4a/b                  2                East Asians     Case (102)               AER \>200 mcg/min                        60/40                 61.0 ± 21.0   NA
  Control (65)                    AER \<20 mcg/min                          46/54                 62.0 ± 10.0      NA                                                                                                                    
  Ksiasek et al. \[[@B13]\]       2003                                      4a/b                  2                Whites          Case (178)               With DN                                  48/52                 57.9 ± 8.2    8.7 ± 3.1
  Control (232)                   Without DN                                51/49                 58.3 ± 6.8       8.0 ± 2.6                                                                                                             
  Lin et al. \[[@B25]\]           2002                                      4a/b                  2                East Asians     Case (80)                With DN                                  NA                    NA            NA
  Control (48)                    Normoalbuminuria                          NA                    NA               NA                                                                                                                    
  Mollsten et al. \[[@B26]\]      2006                                      G894T, 4a/b           1                Whites          Case (955)               AER \>20 mcg/min                         58/42                 40.3 ± 10.0   28 (5--65)
  Control (555)                   AER \<20 mcg/min + DM duration \>20 yrs   41/59                 42.2 ± 10.2      28 (20--57)                                                                                                           
  Mollsten et al. \[[@B18]\]      2009                                      G894T                 1                Whites          Case (458)               AER \>300 mg/24 h                        39/61                 42.0 ± 10.4   27 (7--65)
  Control (319)                   AER \<30 mg/24 h                          55/45                 43.7 ± 11.0      23 (15--63)                                                                                                           
  Neuguebauer et al. \[[@B14]\]   2000                                      4a/b                  2                East Asians     Case 1 (104)             AER 20--200 mg/g Cr                      53/47                 59.0 ± 11.1   13.8 ± 5.1
  Case 2 (39)                     AER \>200 mg/g Cr                         74/26                 59.0 ± 8.6       15.2 ± 4.5                                                                                                            
  Control (82)                    AER \<20 mg/g Cr                          65/35                 56.0 ± 8.6       13.3 ± 4.5                                                                                                            
  Rahimi et al. \[[@B27]\]        2012                                      G894T                 2                West Asians     Case 1 (68)              Albumin to creatinin ratio \>300 mg/g    33/35                 57.1 ± 8.7    11.1 ± 6.4
  Case 2 (72)                     Albumin to creatinin ratio 30--299 mg/g   23/46                 55.3 ± 8.6       8.6 ± 5.2                                                                                                             
  Control (72)                    Albumin to creatinin ratio \<30 mg/g      23/49                 54.4 ± 7.9       7.7 ± 5.4                                                                                                             
  Rippin et al. \[[@B28]\]        2003                                      4a/b                  1                Whites          Case (464)               Overt proteinuria                        NA                    NA            NA
  Control (396)                   Normoalbuminuria                          NA                    NA               NA                                                                                                                    
  Santos et al. \[[@B29]\]        2009                                      G894T, 4a/b, T-786C   2                Whites          Case (376)               AER \>20 mcg/min or \>17 mg/dl           57/43                 60.4 ± 9.7    15.0 ± 9.1
  Control (268)                   AER \<20 mcg/min or \<17 mg/dl            37/63                 62.0 ± 9.4       16.7 ± 6.8                                                                                                            
  Shestakova et al. \[[@B16]\]    2006                                      4a/b                  1                Whites          Case (63)                AER \>300 mg/24 h                        47/53                 25.7 ± 6.4    12.6 ± 2.8
  Control (66)                    AER \<30 mg/24 h                          37/63                 40.8 ± 10.2      26.8 ± 6.9                                                                                                            
  Shimizu et al. \[[@B30]\]       2002                                      4a/b                  2                East Asian      Case 1 (107)             Overt proteinuria                        70/30                 63.1 ± 10.6   15.5 ± 11.0
  Case 2 (124)                    Overt proteinuria + Cr \>1.5 mg/dl        75/25                 65.1 ± 8.8       19.8 ± 7.8                                                                                                            
  Control (203)                   Normoalbuminuria \> DM \>10 yrs           65/35                 63.7 ± 8.8       18.6 ± 7.8                                                                                                            
  Shin Shin et al. \[[@B31]\]     2004                                      G894T                 2                East Asians     Case 1 (35)              Microalbuminuria                         46/54                 62.9 ± 10.9   16 (12--20)
  Case 2 (83)                     Overt proteinuria                         46/54                 58.8 ± 9.7       16 (11--20)                                                                                                           
  Control (59)                    Normoalbuminuric                          25/75                 61.6 ± 11.7      12 (10--16)                                                                                                           
  Shoukry et al. \[[@B32]\]       2012                                      G894T, 4a/b, T-786C   2                African         Case                     Albumin to creatinin ratio \>300 mg/g    108/92                55.3 ± 5.8    14.5 ± 4.3
  Control                         Albumin to creatinin ratio \<30 mg/g      116/84                54.6 ± 5.2       13.8 ± 3.2                                                                                                            
  Tamemoto et al. \[[@B33]\]      2008                                      G894T                 NA               East Asians     Case (124)               Microalbuminuria                         NA                    NA            NA
  Control (211)                   Normoalbuminuria                          NA                    NA               NA                                                                                                                    
  Taniwaki et al. \[[@B20]\]      2001                                      4a/b                  2                East Asians     Case 1 (44)              Microalbuminuria                         59/41                 60.5 ± 8.5    10.9 ± 7.4
  Case 2 (22)                     Overt proteinuria                         68/32                 59.0 ± 10.5      12.8 ± 6.5                                                                                                            
  Case 3 (20)                     Overt proteinuria + Cr \>1.5 mg/dl        50/50                 64.2 ± 7.8       19.1 ± 9.7                                                                                                            
  Control (69)                    Normoalbuminuria                          59/41                 60.1 ± 9.8       7.4 ± 4.5                                                                                                             
  Tiwari et al. \[[@B19]\]        2009                                      G894T                 2                South Asians    Case 1 (90)              DM \>2 yrs + Cr \>2 mg/dl from N India   87/13                 53.6 ± 11.0   9.6 ± 6.8
  Case 2 (106)                    DM \>2 yrs + Cr \>2 mg/dl from S India    76/24                 55.9 ± 11.5      14.0 ± 6.4                                                                                                            
  Control 1 (75)                  DM \>10 yrs + Cr \<2 mg/dl from N India   53/47                 61.0 ± 8.9       15.4 ± 8.1                                                                                                            
  Control 2 (149)                 DM \>10 yrs + Cr \<2 mg/dl from S India   68/32                 60.5 ± 11.4      15.5 ± 6.91                                                                                                           
  Zanchi et al. \[[@B17]\]        2000                                      4a/b, T-786C          1                Whites          Case 1 (74)              AER \>200 mcg/mg                         42/58                 35.5 ± 7.3    24.9 ± 9.0
  Case 2 (78)                     AER \>200 mcg/mg + Cr \>1.5 mg/dl         49/51                 35.7 ± 6.5       24.5 ± 6.8                                                                                                            
                                                                                                                                   Control (195)            AER \<20 mcg/mg + DM \>15 yrs            52/48                 36.5 ± 7.6    23.7 ± 6.3

Where: AER : albumin excretion rate; DM: diabetes mellitus; DN: diabetic nephropathy; NA: not available; Cr: creatinine.

###### 

Polymorphisms distribution

  -------------------------------- --------------------------------------------- -------------- ------------- -------- -------- -------- -----------
  **Author**                        **Distribution of the T-786C polymorphism**     **HWE**                                              
  **Cases**                                        **Controls**                   **p value**                                            
                                                      **TT**                         **TC**        **CC**      **TT**   **TC**   **CC**        
  Ahluwalia et al. \[[@B21]\]                           121                            62            12         165       87       3        0.020
  Ezzidi et al. \[[@B10]\]                              261                           215            34         224      139       32       0.115
  Santos et al. 2011 \[[@B29]\]                         140                           160            76          93      104       44       0.138
  Shoukry et al. 2012 \[[@B32]\]                        57                             89            54          84       83       33       0.129
  Zanchi et al. \[[@B17]\]                              57                             65            30          75      100       20       0.123
                                    **Distribution of the G894T polymorphism**      **HWE**                                              
                                                     **Cases**                    **Controls**   **p value**                             
                                                      **GG**                         **GT**        **TT**      **GG**   **GT**   **TT**        
  Ahluwalia et al. \[[@B21]\]                           82                             81            32         125      105       25       0.658
  Bessa et al. 2011 \[[@B22]\]                          10                             18            12          17       19       4        1.000
  Cai et al. \[[@B23]\]                                 65                             44             7         148      109       27       0.310
  Ezzidi et al. \[[@B10]\]                              185                           247            81         165      195       41       0.151
  Mollsten et al. \[[@B34]\]                            492                           365            89         268      232       51       0.919
  Mollsten et al. \[[@B18]\]                            293                           133            32         182      121       16       0.540
  Rahimi et al. 2012 \[[@B27]\]                         68                             45            13          39       17       7      **0.038**
  Santos et al. 2011 \[[@B29]\]                         176                           166            32         118       95       22       0.640
  Shin Shin et al. \[[@B31]\]                           95                             23             0          52       7        0        1.000
  Shoukry et al. 2012 \[[@B32]\]                        66                             94            40          99       77       24       0.140
  Tamemoto et al. \[[@B33]\]                            104                            18             2         181       27       3        0.117
  Tiwari et al. \[[@B19]\]                              82                             21             3          91       43       13     **0.035**
                                    **Distribution of the 4b/4a polymorphism**      **HWE**                                              
                                                     **Cases**                    **Controls**   **p value**                             
                                                      **bb**                         **ba**        **aa**      **bb**   **ba**   **aa**        
  Ahluwalia et al. \[[@B21]\]                           146                            28            21         189       61       5        1.000
  Degen et al. \[[@B24]\]                               229                            94             4         297      105       9        1.000
  Ezzidi et al. \[[@B10]\]                              314                           162            29         234      143       21       1.000
  Fujita et al. \[[@B25]\]                              81                             21             0          55       10       0        1.000
  Ksiasek et al. 2003 \[[@B13]\]                        105                            58            15         147       66       19     **0.007**
  Lin et al. \[[@B26]\]                                 115                            21             1          41       6        1        0.271
  Mollsten et al. \[[@B34]\]                            656                           248            39         389      145       19       0.220
  Neugebauer et al. \[[@B14]\]                          101                            26             6          71       10       1        0.351
  Rippin et al. \[[@B28]\]                              344                           108            12         297       90       9        0.519
  Santos et al. 2011 \[[@B29]\]                         237                            99            11         168       59       5        1.000
  Shestakova et al. \[[@B16]\]                          14                             48             1          34       31       1        0.052
  Shimizu et al. \[[@B30]\]                             180                            44             6         156       44       3        1.000
  Shoukry et al. 2012 \[[@B32]\]                        124                            64            12         131       60       9        0.502
  Taniwaki et al. \[[@B20]\]                            63                             21             2          50       19       0        0.340
  Zanchi et al. \[[@B17]\]                              80                             27            37         144       47       4        1.000
  -------------------------------- --------------------------------------------- -------------- ------------- -------- -------- -------- -----------

HWE (Hardy-Weinberg equilibrium).

Hardy-Weinberg equilibrium (HWE) was assessed using exact test and P-value \< 0.05 were considered significant. Only 4 studies (1 study for T-786C; 2 for G984T; and 1 for 4b/a) with controls were not in HWE (Table  [2](#T2){ref-type="table"}). These studies were subjected to a sensitive analysis, and their exclusion did not show significant difference on OR.

For the 4b/a polymorphism, an association with DN in all genetic models, except for co-dominance, was observed: allele contrast (OR = 1.15, CI (95%): 1.05-1.25, P~Q~ \<0.01, I^2^ = 66%); additive (OR = 1.52, CI (95%): 1.18-1.97, P~Q~ \<0.01, I^2^ = 62%); recessive (OR = 1.50, CI (95%): 1.16-1.93, P~Q~ \<0.01, I^2^ = 64%); and dominant (OR = 1.11, CI (95%): 1.01-1.23, P~Q~ = 0.01, I^2^ = 49%). Similarly, for the T-786C polymorphism the association with DN was found with all models, with exception for co-dominance model: allele contrast (OR = 1.22, CI (95%): 1.07-1.39, P~Q~ = 0.59, I^2^ = 0%), additive (OR = 1.52, CI (95%): 1.18-1.97, P~Q~ \< 0.01, I^2^ = 62%), recessive (OR = 1.50, CI (95%): 1.16-1.93, P~Q~ \<0.01, I^2^ = 64%) and dominant (OR = 1.11, CI (95%): 1.01-1.23, P~Q~ \<0.01, I^2^ = 49%). The G894T polymorphism showed association with DN in allelic contrast (OR = 1.12, CI (95%): 1.03-1.25, P~Q~ \<0.01, I^2^ = 75%) and co-dominance model (OR = 1.13, CI (95%): 1.04-1.37, P~Q~ = 0.01, I^2^ = 60%) (Table  [3](#T3){ref-type="table"} and Figure  [2](#F2){ref-type="fig"}). A random model analysis was performed confirming the fixed model results.

###### 

**Meta-analysis in all genetic models with all patients and subgroup analysis, in fixed-model analysis, presenting heterogeneity (P**~**Q**~**and I**^**2**^**)**

                        **Population**    **Studies**     **OR**      **IC (95%)**   **P**    **P**~**Q**~   **I**^**2**^**(%)**
  --------------------- ---------------- ------------- ------------- -------------- -------- -------------- ---------------------
  **4b/a**                                                                                                             
  **Allele contrast**   All                   15           1.15        1.05-1,25     \<0.01      \<0.01              66
  African               2                    0,98        0.81-1.18        0.88        0,25         22       
  East Asians           6                    1.21       0.97-1.50.8       0.08        0.29         18       
  Whites                7                    1.20        1.07-1.34       \<0.01      \<0.01        80       
  Type 1                5                    1.17        1.02-1.34        0.02        0.07         54       
  Type 2                10                   1.12        0.99-1.27        0.07        0.28         18       
  **Additive**          All                   15           1.52        1.18-1.97     \<0.01      \<0.01              62
                        African                2           1,13        0,69-1,81      0.62        0.56                0
                        East Asians            6           3.25        1.58-6.68     \<0.01       0.31               16
  Whites                7                    1.49        1.06-2.08        0.01       \<0.01        74       
  Type 1                5                    2.21        1.50-3.25       \<0.01      \<0.01        81       
  Type 2                11                   1.36        0.98-1.88        0.06        0.08         41       
  **Recessive**         All                   15           1.50        1.16-1.93     \<0.01      \<0.01              64
                        Africans               2           1.13        0.69-1.83      0,61        0.83                0
                        East Asians            6           3.44        1.68-7.05     \<0.01       0.28               21
  Whites                7                    1.43        1.03-1.99        0.03       \<0.01        75       
  Type 1                5                    2.19        1.49-3.21       \<0.01      \<0.01        81       
  Type 2                11                   1.49        1.07-2.07        0.02        0.08         42       
  **Dominant**          All                   15           1.11        1.01-1.23      0.03        0,01               49
                        African                2           0.94        0.75-1.18      0.64        0.24               27
                        East Asians            6           1.04        0.81-1.34      0.71        0.44                0
  Whites                7                    1.20        1.05-1.36       \<0.01      \<0.01        67       
  Type 1                5                    1.22        1.04-1.43        0.01       \<0.01        78       
  Type 2                11                   1.05        0.92-1.20        0.44        0.62         0        
  **Codominant**        All                   15           0.98        0.88-1.09      0.81        0,02               46
                        African                2           1.09        0.87-1.38      0.42        0.29                7
                        East Asians            6           1.17        0.90-1.55      0.22        0.14               38
  Whites                7                    0.90        0.79-1.04        0.16        0.04         54       
  Type 1                5                    0.94        0.80-1.11        0.46        0.01         68       
  Type 2                11                   1.01        0.88-1.17        0.80        0.19         26       
  **T-786C**                                                                                                           
  **Allele contrast**   All                    5           1.28        1.14-1.44     \<0.01       0.25               24
  African               2                    1.44        1.21-1.71       \<0.01       0.26         19       
  Whites                2                    1.13        0.94-1.36        0.19        0.44         0        
  Type 2                4                    1.29        1.13-1.46       \<0.01       0.15         42       
  **Additive**          All                    5           1.48        1.14-1.92     \<0,01       0.01               67
                        African                2           1.43        0.98-2.09      0.05        0.01               84
                        Whites                 2           1.36        0.93-1.98      0.10        0.18               42
  Type 2                4                    1.40        1.06-1.86        0.01       \<0.01        73       
  **Recessive**         All                    5           1.38        1,09-1.76     \<0,01       0.01               68
                        African                2           1.24        0.88-1.76      0.21        0.01               81
                        Whites                 2           1.39        0.98-1.95      0.06        0.09                0
  Type 2                4                    1.27        0.98-1.65        0.06        0.01         72       
  **Dominant**          All                    5           1.21        1,04-1.42      0.01        0.29               18
                        African                2           1.39        1.11-1.73     \<0.01       0.13               54
                        Whites                 2           1.05        0.81-1.37      0.70        0.95                0
  Type 2                4                    1.24        1.05-1.47       \<0.01       0.22         31       
  **Codominant**        All                    5           0.95        0.81-1.11      0.53        0.12               45
                        African                2           0.78        0.62-0.98      0.03        0.48                0
                        Whites                 2           1.15        0.89-1.49      0.28        0.24               25
  Type 2                3                    0.90        0.75-1.06        0.20       0.131         15       
  **G986T**                                                                                                            
  **Allele contrast**   All                   12           1.12        1.03-1.21     \<0.01      \<0.01              75
  African               3                    1.63        1.39-1.91       \<0.01       0.61         0        
                        East Asian             3           1.33        1.05-1.70      0.01        0.74                0
  Whites                4                    0.93        0.84-1.04        0.20        0.67         0        
  Type 1                2                    0.92        0.80-1.04        0.18        0.18         0        
  Type 2                9                    1.27        1.15-1.42       \<0.01      \<0.01        72       
  **Additive**          All                   12           1.19        0.99-1.43      0.05       \<0.01              63
                        African                3           2.01        1.50-2.94     \<0.01       0.27               22
                        East Asian             3           1.85        1,05-3.25      0.03        0.59                0
  Whites                4                    0.86        0.67-1.10        0.23        0.69         0        
  Type 1                2                    0.87        0.65-1.16        0.34        0.44         0        
  Type 2                9                    1.47        1.16-1.86       \<0.01      \<0.01        63       
  **Recessive**         All                   12           1.16        0.97-1.38      0.09        0.02               52
                        Africa                 3           1.80        1.31-2.46     \<0.01       0.43                0
                        East Asian             3           1.73        1.01-2.96      0.04        0.63                0
                        Whites                 4           0.88        0.69-1.11      0.29        0.62                0
  Type 1                2                    0.91        0.69-1.20        0.49        0.31         0        
  Type 2                9                    1.36        1.08-1.70       \<0.01       0.03         53       
  **Dominant**          All                   12           0.99        0.89-1.11      0.92        0.07               45
                        African                3           1.46        1.17-1.82     \<0.01       0.11               54
                        East Asian             3           1.32        0.98-1.79      0.06        0.73                0
                        Whites                 4           0.93        0.80-1.07      0.31        0.59                0
  Type 1                2                    0.89        0.75-1.06        0.19        0.74         0        
  Type 2                9                    1.19        0.92-1.26        0.35        0.04         57       
  **Codominant**        All                   12           1.03        1.04-1.37      0.01        0.01               60
                        African                3           0.92        0.74-1.14      0.45        0.29               18
                        East Asian             3           0.89        0.65-1.21      0.48        0.52                0
                        Whites                 4           1.02        0.89-1.18      0.69        0.44                0
  Type 1                2                    1.08        0.91-1.29        0.35        0.32         0        
                        Type 2                 9           0.94        0.82-1.08      0.41        0.34               11

![Forest plot for contrast allele model for (A) 4b/a polymorphism; (B) T-786C polymorphism; and (C) G894T polymorphism.](1471-2350-15-9-2){#F2}

Publication bias was observed for the majority of the polymorphisms evaluated and are presented as a funnel plot for 4b/a polymorphsism (Figure  [3](#F3){ref-type="fig"}). In order to identify non published data, we performed manual search for abstracts in some of the major scientific meetings in the field in the last seven years. We estimated the effect of these potential publication biases using trim and fill method and no major differences were observed from the original results.

![Funnel plot for 4b/a polymorphism: (A) allele contrast; (B) additive; (C) recessive; (D) dominant; (E), codominant.](1471-2350-15-9-3){#F3}

Since some studies included only subjects of specific ethnicities or with type 1 or type 2 DM, we performed a sensitive analysis stratifying the studies according to these characteristics. Considering 4b/a polymorphism, there was an association in White and East Asian populations in allele contrast, additive and recessive models; only for Whites in the dominant model; and none for the co-dominant model. For T-786C variant, no association was shown for Whites in allele contrast analysis or in any other genetic model, but in African populations the polymorphism was associated with DN in allele contrast, dominance and co-dominance models. Considering G894T polymorphism, in African populations the association was observed for all genetic models, with the exception of co-dominance model. There were insufficient studies to perform a meta-analysis for G894T in South Asians and West Asians.

According to the type of diabetes mellitus (DM), for 4b/a polymorphism an association was observed in additive and recessive models for both type 1 and type 2 diabetes, and only for type 1 in allele contrast and dominant models. There was no association with any type of DM in co-dominant model for 4b/a variant. For T-786C, no association in any genetic model was found in type 2 diabetes. There was insufficient data for this analysis in type 1 DM. Likewise, for G894T variant there was an association only in the allele contrast model with type 2 diabetes (Table  [3](#T3){ref-type="table"}).

We compared the ORs of our meta-analysis with the results from a previous meta-analysis that used non-diabetic patients as controls \[[@B30]\]. The results were similar and no statistical differences in the ORs of the two studies were observed in all genetic models analyzed (data not shown).

Conclusions
===========

In the present study, the most robust association of DN was with eNOS 4b/a and T-786C polymorphism that held in all genetic models tested, except for co-dominance model. G894T polymorphism was associated with DN only in allele contrast and in co-dominance model. 4b/a polymorphism association with DN was confirmed in all ethnic groups evaluated and for all types of diabetes. The subgroup analysis of the T-786C variant should be viewed with caution, since it was limited due to the small number of studies.

Analyzing genetic model is important, considering the difference between them. Each individual genotype is formed by two alleles (for example G and T for G984T polymorphism), and the risk of every genotype depends on the number of variant allele copies carried, where one of which is thought to be associated with a disease (e.g., T), association studies will collect information on the numbers of diseased and disease-free subjects with each of the three genotypes (GG, GT, and TT). So we used the allele contrast, which compares the number of alleles G with the number of alleles G; the additive model, which contrasts extreme homozygotes, comparing the genotype GG with the genotype TT; in recessive model two copies of T allele are essential to modify the risk, combining the GG and GT genotypes and comparing with TT; the dominant model, which heterozygous GT and homozygous TT genotypes have the similar risk as a single copy of T is sufficient to alter the risk, then compares GG with combined GT and TT genotypes; and the codominance model, commonly used genetic model, where each genotype gives a diverse and non additive risk. which combines the GG and TT genotypes and compares with GT. So OR in each particular genetic model gives us different interpretations about the risk of the polymorphisms.

These results are original and help to understand the role of these polymorphisms in the development of DN. However, it was not possible to exclude a publication bias of negative studies. Therefore, the exact effect could be smaller. As discussed before, other explanations, besides classic risk factors, are needed for understanding the progression of a diabetic patient from normoalbuminuria to macroalbuminuria, and a polymorphism identification of a specific gene would propitiate the development of a new therapy aimed directly to it.

In contrast to a recent meta-analysis performed by Zintzaras et al. \[[@B30]\], which analyzed the same polymorphisms in the progression of DN, our analysis compared diabetic patients with DN (cases) with diabetic patients without DN (controls). In Zintzaras' study, healthy subjects were used as controls, mixed with patients with DN. When the controls are defined as non-diabetic subjects, the observed association could reflect a genetic predisposition for individuals to develop "diabetic nephropathy". The obtained results could reflect a mixture of a susceptibility to diabetes per se and to nephropathy, which cannot be discriminated. In this regard, to serve non-diabetic individuals as controls seem rationale to estimate a risk of diabetic nephropathy. However, from clinical points of view, most of medical staff would be interested in risks for nephropathy among individuals with diabetes, as in the case with hyperglycemia, rather than combined risks for developing diabetes and for nephropathy thereafter. That is why diabetic individuals showing no or little nephropathy despite a term of duration have been widely investigated as controls, in most of the previous studies. So, our work and Zintzaras are derived from different standing points: a clinical aspect and a bio-mathematic research.

In this sense, we considered that the optimal control group when studding a DM complication is a diabetic patient without the complication and with disease duration long enough the permit a genetic predisposition to become clinically detected in the presence of hyperglycemia. Moreover, the disease duration must be comparable between cases and controls. Most included studies fulfilled the two pre-requisitions. As can be seen in Table  [1](#T1){ref-type="table"}, the DM duration is similar between cases and controls in each study and the majority has more than 10 years of DM, reflecting that authors from original studies probably took this important issue in consideration.

Despite the different control used by Zintzaras, they found 92 articles, being 20 included for meta-analysis; that provided 1942/1461 cases/controls for G894T, 2663/2232; cases/controls for 4b/a, and 857/845 cases/controls for T-786C. That was similar to ours that had 22 studies included, but provided about one third more cases/controls. The OR observed in their analyzes showed significance in allelic contrast model for G894 polymorphism, recessive and additive model for 4b/a polymorphism, and allelic contrast model for T-786C, all observed in our study; but our analyze showed association in more genetic models than that, like codominant model for G894T; allele contrast and dominant model for 4b/a; recessive, dominant and additive model for T786C. Furthermore, we compared our ORs with those reported by Zintzaras et al. and no statistical differences were found. With that said, our study reinforce the findings from Zintzaras.

DN development predisposition has not been fully explained, since glycemic control and environmental factors, as well as traditional risk factors, do not accurately predict the occurrence of this diabetic complication in all patients. With this in mind, studies have been trying to resolve this question using genetic approaches. Many candidate genes have been explored in this context, and eNOS polymorphisms have been implicated in the susceptibility to glomerular disease, by mechanisms yet unknown \[[@B15]\]. However, there is no consensus on the role of these polymorphisms in modulation of risk for DN, since the available literature demonstrates mixed results and most of the studies have a small sample. In this scenario, the recommended approach to help investigators in understanding the effect of each polymorphism in DN development is a systematic review and meta-analysis. Our data suggest an association between eNOS polymorphisms and DN. Assuming a recessive model, the relative risk, attributable risk and population attributable risk for the 4a variant ranges are, respectively, 1.20; 0.11; and 0.09.

The present paper has some limitations. The inclusion of studies evaluating patients with DM in several stages of DN, ranging from microalbuminuria to chronic renal insufficiency in kidney replacement therapy, could bias the results due to clinical heterogeneity of cases. Some studies did not present the data separated by DN stages. Furthermore, inclusion criteria in the reviewed studies utilized different methods and cutoffs to define microalbuminuria or macroalbuminuria. Although all clinically validated \[[@B35]\], these aspects made impossible to evaluate the effect of each polymorphism in the stages of DN in this meta-analysis. Finally, the polymorphisms true effects could be overestimated in the present study, since there is some indication of publication bias.

In conclusion, this study shows an association between DN and polymorphisms in eNOS gene. This effect is very consistent for the 4b and T-786 polymorphism.

Methods
=======

The Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) statement was used in this report \[[@B36],[@B37]\].

Selection criteria and search strategy
--------------------------------------

Case--control studies that had diabetic patients with DN as cases and diabetic patients without nephropathy as controls, as well as that evaluated at least one of the three polymorphisms of interest (4b/4a, T-786C, G986T) were considered eligible. Only studies in humans and using validated genotyping methods were considered. No publication language, publication date, or publication status restrictions were imposed. All studies published up until December 31^st^, 2012 were identified by searching electronic databases: Medline (1966-Present), EMBASE (1980-Present), LILACS and Cochrane Library.

Abstracts presented at scientific events held by: The American Diabetes Association (ADA); The European Association for the Study of Diabetes (EASD); The National Kidney Association (NKA); and The American Society of Nephrology (ASN) were searched over the last seven years. The authors were contacted for more details in the case of abstracts with missing information.

The following index terms were used: ("Nitric Oxide Synthase Type III" OR "NOS3 protein, human") AND ("Databases, Genetic" OR "Genetic Predisposition to Disease" OR "Genetic Phenomena" OR "Genetic Processes" OR "Genetic Markers" OR "Genetic Variation" OR "Polymorphism, Genetic" OR "Genetic Research" OR "Genetic Determinism" OR "Genes" OR "Genetics" OR "Mutation" OR "Genetics, Medical" OR "DNA") AND ("Proteinuria" OR "Albuminuria" OR "Kidney Failure" OR "Kidney Failure, Chronic" OR "Kidney Diseases" OR "Diabetic Nephropathies").

Study selection and data extraction
-----------------------------------

Eligibility assessment was made by title and abstracts review and in doubtful cases by full article review. This was performed independently in a standardized manner by two investigators (BSD and CBL). Disagreements between reviewers were resolved by consensus.

Two investigators extracted the data, one independent to another (BSD and LCFP). Disagreements were resolved by a third author (LHC). For articles with missing information, (n = 3) the authors were contacted for further information, but none responded. In the case of duplicate publications, the first manuscript published was included in the analysis. Information was extracted from each individual study based on: (1) characteristics of study participants (including age, gender, type of diabetes, diabetes duration, nephrologic status, and ethnicity) \[[@B38]\], (2) case and control definition; (3) genetic data (including allelic distribution and genotypic frequency).

Quality assessment
------------------

To ascertain the validity of each eligible case--control study, two investigators (BSD and LCFP) worked independently during the initial search and after worked together to determine the adequacy of studies selection. It was assessed if the same exclusion criteria for cases and controls were used; if cases were easily differentiated from controls; if analysis of studied polymorphisms were conducted in a standard, valid, and reliable way, if major biases were identified and considered in design and analysis; and how good the study was to minimize the risks of bias or confusion. Hardy-Weinberg equilibrium assessment among the control group within each polymorphism in all studies was checked by exact test using an online HWE calculator (<http://ihg.gsf.de/cgi-bin/hw/hwa1.pl>).

Statistical analysis
--------------------

Gene-disease association was measured using odds ratio estimation based on the following genetic contrast/models: (1) allele contrast; (2) additive model; (3) recessive model; (4) dominant model and (4) co-dominant model \[[@B39],[@B40]\]. Heterogeneity was tested by chi-squared test, Cochran's Q, and inconsistency with I^2^. If P~Q~ \<0.10, then heterogeneity was considered statistically significant. Odds ratio was calculated using fixed-effect models (Mantel-Haenszel), and random models when heterogeneity was observed. Multiple comparisons were not made because meta-analysis of genetic association studies is considered an exploratory study, without a prespecified key hypothesis \[[@B41],[@B42]\].

The risk of publication bias was evaluated using funnel plot graphics \[[@B43]\].

Sensibility tests were made concerning to ethnia and type of diabetes.

Data were analyzed using Stata/SE 11.2 (<http://www.stata.com>).

We compared the ORs of our meta-analysis with the results from a previous one \[[@B44]\] that used non-diabetic patients as controls using the differences of OR and 95%CI (WinPepi version 11.3).
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